Savara Inc (NASDAQ:SVRA) CEO Matthew Pauls Sells 54,702 Shares

Savara Inc (NASDAQ:SVRA) CEO Matthew Pauls sold 54,702 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the sale, the chief executive officer now owns 1,536,379 shares of the company’s stock, valued at approximately $5,085,414.49. This trade represents a 3.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Savara Trading Up 1.6 %

Savara stock opened at $3.26 on Tuesday. Savara Inc has a 12-month low of $2.82 and a 12-month high of $5.70. The firm has a market capitalization of $559.48 million, a price-to-earnings ratio of -7.58 and a beta of 0.92. The firm has a 50 day moving average of $3.51 and a 200 day moving average of $4.01. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11). As a group, research analysts predict that Savara Inc will post -0.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on SVRA. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price target on shares of Savara in a research report on Tuesday, October 1st. HC Wainwright reduced their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Finally, Evercore ISI reiterated an “in-line” rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.17.

Institutional Investors Weigh In On Savara

A number of institutional investors have recently bought and sold shares of the business. Vestal Point Capital LP boosted its stake in shares of Savara by 24.7% in the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock worth $34,302,000 after acquiring an additional 1,600,000 shares during the period. Frazier Life Sciences Management L.P. lifted its holdings in Savara by 103.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after purchasing an additional 4,157,385 shares in the last quarter. Nantahala Capital Management LLC boosted its stake in Savara by 198.2% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after purchasing an additional 3,443,541 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Savara by 54.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 690,609 shares of the company’s stock valued at $2,928,000 after buying an additional 242,249 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Savara by 238.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company’s stock valued at $3,865,000 after buying an additional 642,259 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.